About Cytochrome P450 4B1
Cytochrome P450 4B1 (CYP4B1) is a protein
from Homo sapiens identified by UniProt accession
P13584, 511 residues long.
MolForge cross-references it against 0 known binders and
98 disease associations.
Target properties
| Protein name | Cytochrome P450 4B1 |
| UniProt accession | P13584 |
| Gene | CYP4B1 |
| Organism | Homo sapiens |
| Length | 511 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (98)
Diseases linked to this target (Open Targets).
- cutaneous melanoma · score 0.26
- glioblastoma multiforme · score 0.23
- lung adenocarcinoma · score 0.21
- head and neck squamous cell carcinoma · score 0.13
- serum metabolite measurement · score 0.12
- urinary bladder cancer · score 0.11
- urinary metabolite measurement · score 0.08
- breast cancer · score 0.07
- blood metabolite measurement · score 0.07
- lung carcinoma · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P13584-F1 | alphafold | PREDICTED | 94.08 | — |
Amino-acid sequence (511 residues)
MVPSFLSLSF SSLGLWASGL ILVLGFLKLI HLLLRRQTLA KAMDKFPGPP THWLFGHALE IQETGSLDKV VSWAHQFPYA HPLWFGQFIG FLNIYEPDYA KAVYSRGDPK APDVYDFFLQ WIGRGLLVLE GPKWLQHRKL LTPGFHYDVL KPYVAVFTES TRIMLDKWEE KAREGKSFDI FCDVGHMALN TLMKCTFGRG DTGLGHRDSS YYLAVSDLTL LMQQRLVSFQ YHNDFIYWLT PHGRRFLRAC QVAHDHTDQV IRERKAALQD EKVRKKIQNR RHLDFLDILL GARDEDDIKL SDADLRAEVD TFMFEGHDTT TSGISWFLYC MALYPEHQHR CREEVREILG DQDFFQWDDL GKMTYLTMCI KESFRLYPPV PQVYRQLSKP VTFVDGRSLP AGSLISMHIY ALHRNSAVWP DPEVFDSLRF STENASKRHP FAFMPFSAGP RNCIGQQFAM SEMKVVTAMC LLRFEFSLDP SRLPIKMPQL VLRSKNGFHL HLKPLGPGSG K
Explore Cytochrome P450 4B1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets